問卷

TPIDB > Principal Investigator

Principal Investigator


MacKay Memorial Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of General Internal Medicine

MacKay Memorial Hospital

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間:2023-09-19

王蒼恩
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

32Cases

2011-12-01 - 2016-07-31

Phase II

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (Shine study)
  • Condition/Disease

    Advanced Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD4547

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)
  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 1 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2008-01-01 - 2010-01-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2013-02-07 - 2020-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection
  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

2011-08-30 - 2014-07-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Terminated17Sites

1 2 3 4